This is a great question and one I’ve pondered myself a lot when...

This is a great question and one I’ve pondered myself a lot when speculating on the future value of CU6. I think if we keep seeing good results generated through clinical trials, then this becomes the most critical directional decisions.

If strong demand for CU6’s products eventuates, then manufacturing and distribution would become their biggest challenge. Having that capacity within the company would certainly lift their valuation. I don’t believe the difficulty would be in designing/building/funding, but in managing/operating as a going concern. Isotope and final product manufacture and distribution is a complex and hazardous business to be in and if their core focus remains on getting new products through the pipeline, then the path of setting up manufacturing facilities could be too distracting.

Personally, I think it’d be fantastic for CU6 to end up with manufacturing and distribution facilities, but only if the resources are available. For now - the direction and progress has been exemplary.